Has April Coughlan received payments from drug or device companies?

Yes. Drug and device makers reported $4,784 in general payments to April Coughlan across 213 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean April Coughlan did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about April Coughlan come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

April Coughlan

Family · Miami, FLNPI 1710373667

Payments from drug & device makers

$4,784in general payments, 2019–2025

Across 213 payments — averaging $22.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Incyte Corporation$457
Pfizer$435
Johnson & Johnson$398
Jazz Pharmaceuticals Inc.$320
E.r. Squibb & Sons, L.L.C.$274
AstraZeneca$264
plus $3K from 38 others

What the payments were for

Food & beverage$4,26689%
Education$51811%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Incyte Corporation	18	$457
Pfizer	20	$435
Johnson & Johnson(2 entities)	15	$398
Jazz Pharmaceuticals Inc.	9	$320
E.r. Squibb & Sons, L.L.C.	6	$274
AstraZeneca(2 entities)	11	$264
Merck	13	$243
Novartis	13	$228
Pharmacyclics LLC, An Abbvie Company	10	$228
Seagen Inc.	7	$181
Bristol Myers Squibb	8	$135
Amgen	8	$126
Daiichi Sankyo Inc.	7	$118
AbbVie	5	$112
Eisai Inc.	5	$105
Genmab U.S., Inc.	1	$104
Lilly USA, LLC	6	$91
Boehringer Ingelheim	4	$69
Sanofi	4	$67
AMAG Pharmaceuticals, Inc.	4	$67
G1 Therapeutics, Inc.	4	$63
Bayer	3	$59
Array Biopharma Inc	2	$48
Gilead	3	$45
Karyopharm Therapeutics Inc.	2	$43
Taiho Oncology, Inc.	1	$43
Foundation Medicine, Inc.	2	$42
Coherus Oncology, Inc.	1	$39
Morphosys, US Inc.	2	$37
GSK	2	$36
Astellas Pharma US Inc	2	$36
Alnylam Pharmaceuticals Inc.	2	$34
Takeda Pharmaceuticals U.S.A., Inc.	2	$31
AVEO Pharmaceuticals, Inc.	1	$23
Pharmaessentia USA Corporation	1	$22
Recordati_rare_diseases_inc.	1	$21
GE HealthCare	1	$20
Genentech USA, Inc.	1	$19
Sobi, Inc	1	$19
Servier Pharmaceuticals LLC	1	$18
Myriad Genetic Laboratories, Inc.	1	$18
Puma Biotechnology, Inc.	1	$17
Dova Pharmaceuticals	1	$15
ADC Therapeutics America, Inc.	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Pomalyst$111
EPKINLY$104
INLYTA$101

How this compares

$4,784 in reported general payments places this provider in the 90th percentile of 14,618 family providers in Florida.

See all family providers in Florida →

Medicare billing

Part B allowed, 2024

$19,379

Medicare patients

106

Services billed

268

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Anastrozole	57	$1,287
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	19	$305
Dexamethasone	16	$279
Hydroxyurea	16	$247
Acyclovir	14	$246
Mirtazapine	25	$232
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen	11	$222
Allopurinol	11	$204
Ondansetron OdtOndansetron	13	$180
Levothyroxine Sodium	28	$66
Pentoxifylline	11	$26

Paid to pharmacies, not to this prescriber.

Other family in Miami

Stephanie MompointMiami$4.5M
Itsel Cardenas RamonMiami$1M
Patrick SzarazMiami$327K
Yamila MelendezMiami$212K
Suzan RosenMiami$129K
Felipe NovoaMiami$110K
Pamela DudkiewiczMiami$89K
Stacy FeemsterMiami$51K
John HuffakerVenice$8M
Miguel TrujilloMiami Gardens$4.4M

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →